Parents of children with Duchenne muscular dystrophy say they have appealed to the Prosecutor’s Office, accusing police of ...

The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds.

Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the treatment of patients ...

Pratteln, Switzerland, April 28, 2026 - Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE (vam ...

Pratteln, Switzerland, April 28, 2026 -- Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE (R) ...

Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Analyst says Japan's support for Taiwan upends ...

Jon Anning, a Slippery Rock University professor, has done extensive research on effects and treatment for Duchenne muscular ...

A Santa Cruz family received a fully adaptable van for their 12-year-old son with Duchenne muscular dystrophy, funded by ...

Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -WALTHAM, Mass., ...

Gillette Children’s Specialty Healthcare in St. Paul was first to set up special program for providing still-experimental ...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion ...

The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.